Skip to content
OpenCapital
Get started

Biohaven BHVN Available-for-Sale Debt Securities - Unrealized Loss Position (>=12 Months)

Available-for-Sale Debt Securities - Unrealized Loss Position (>=12 Months) at other companies

Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
0—

Other financials

Income statement

See full
Operating income-$130.4M+41.1%
Net income-$130.5M+41.1%
EPS (diluted)-$0.88+59.4%

Balance sheet

See full
Cash & equivalents$277.1M+170%
Total debt$286.2M+706%
Total equity$129.5M-50.1%
Total assets$466.4M+1.6%

Cash flow

See full
Operating cash flow-$149.9M+9.2%
CapEx--100%
Free cash flow-$149.9M+9.5%

Valuation

See full
Market cap$2.25B-48.1%
Enterprise value$2.26B-46.3%

Returns & leverage

See full
Return on equity-333%+17.9pp
Debt / equity2.2×+2.1×
Current ratio7.4×+5.1×

Where this comes from

Reported directly by Biohaven in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions.

The official record: Biohaven’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biohaven's available-for-sale debt securities - unrealized loss position (>=12 months).

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biohaven's available-for-sale debt securities - unrealized loss position (>=12 months)?
Biohaven (BHVN) reported available-for-sale debt securities - unrealized loss position (>=12 months) of 0 in Q1 2026.